Treatment Selection for EDS in Patients With OSA

Panelists discuss how they select between wake-promoting medications (modafinil, armodafinil, and solriamfetol) by explaining neurotransmitter mechanisms to patients while acknowledging that practical factors like insurance coverage and accessibility often drive treatment decisions more than theoretical mechanisms.